

BC Cancer ST Program Updates for November 2022

AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer VC (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- **For PowerPlans that are versioned:** If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop up window will appear to indicate a new version is required.
 - Click **Yes** to accept the new version.
 - **Do not** use the Copy Forward functionality to ensure that the updates apply.




- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below:

PowerPlan: LYIT

Cycles/PowerPlans: All associated treatment PowerPlans

Changes:
In chemotherapy phase:
Updated yellow note from
'Refer to local guidelines for anticoagulation management' to
'Refer to local guidelines for anticoagulation and antiplatelet therapy management'



Versioning: No


Jira: CST-186017

PowerPlan: ULYFACAL, ULYFIBRU

Cycles/PowerPlans: All associated Regimens and PowerPlans

Changes:
CAP designation of these protocols will be removed on November 1, 2022.

New Names in Cerner:
ULYFACAL → LYFACAL
ULYFIBRU → LYFIBRU



Versioning: Yes

Jira: CST-186937, CST-186945


PowerPlan: GOTDEMACO

Cycles/PowerPlans: GOTDEMACO (inpatient and outpatient)

Changes:

In the Inpatient Chemotherapy phase:


- Updated treatment schedule to be Days 1 to 7.
- Added yellow note under etoposide IV: If dose modification is required, omit etoposide IV and choose etoposide PO. If ordering etoposide PO, it must also be ordered in Prescriptions Phase.
- Added PO etoposide for Days 1 to 7.
- Mutually excluded both etoposide orders.

ONCP GO GOTDEMACO (Inpatient and Outpatient) - Cycle 1, Inpatient Chemotherapy (Day 1 to 7) (Future Pending) *Est. 20-Oct-2022 11:02 PDT - 14 Days								
Component	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	
<input checked="" type="checkbox"/> DACTINomycin (DACTINomycin - oncology (CAPPED)) 0.5 mg, IV, once oncology, drug form: syringe-inj INPATIENT Days 1 and 2	Future Pending *Est. 20-Oct-2022 11:02 PDT	Future Pending *Est. 21-Oct-2022 11:02 PDT	Future Pending *Est. 22-Oct-2022 11:02 PDT	Future Pending *Est. 23-Oct-2022 11:02 PDT	Future Pending *Est. 24-Oct-2022 11:02 PDT	Future Pending *Est. 25-Oct-2022 11:02 PDT	Future Pending *Est. 26-Oct-2022 11:02 PDT	Future Pending *Est. 27-Oct-2022 11:02 PDT
<input checked="" type="checkbox"/> etoposide (etoposide - oncology) 100 mg/m ² , IV, once oncology, administer over: 45 minute ... Use non-DEHP tubing with 0.2 micron in-line filter. May ad...	Planned +10 min	Planned +10 min						
 If dose modification is required, omit etoposide IV and choose etoposide PO. If ordering etoposide PO, it must also be ordered in Prescriptions Phase								
<input type="checkbox"/> etoposide (etoposide - oncology) 50 mg, PO, once oncology, drug form: cap, Use Patient Sup... Days 1 to 7		+10 min	+10 min	+10 min	+10 min	+10 min	+10 min	+10 min

Added a new Prescriptions Phase with:

- Yellow note at the top: If dose modification is required, omit etoposide IV and order etoposide PO. If ordering etoposide PO, it must also be ordered in Inpatient Chemotherapy Phase.
- PO etoposide.

ONCP GO GOTDEMACO (Inpatient and Outpatient) - Cycle 1, Prescriptions (Future Pending)

 If dose modification is required, omit etoposide IV and order etoposide PO. If ordering etoposide PO, it must also be ordered in Inpatient Chemotherapy Phase
<input type="checkbox"/> etoposide 50 mg, PO, as directed, Take once daily on days 1-7 of each cycle, drug form: cap, dispense qty: 14 day Dispense quantity = 1 cycle

Versioning: Yes

Jira: CST-186363

PowerPlan: ULYFIBRU, LYIBRU, LYMIBRU

Cycles/PowerPlans: Pretreatment and Treatment powerplans

Changes:

In the Diagnostics Phase:

- Added optional MUGA and Echocardiogram/CARD Echo.

Component	Status	Cost
ONCP LY LYFIBRU Pretreatment Plan, Diagnostics (Future Pending)		
If clinically indicated:		
<input type="checkbox"/>	<input checked="" type="checkbox"/>	Electrocardiogram 12 Lead
<input type="checkbox"/>	<input checked="" type="checkbox"/>	NM MUGA
<input type="checkbox"/>	<input checked="" type="checkbox"/>	CARD Echo

Versioning: Yes

Jira: CST-186945, CST-186947

Jira Ticket #	CST-186947, CST-186945, CST-186937, CST-186363, CST-186017
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Phone Support: 1-844-214-7444